跳至主要内容
临床试验/ISRCTN52370199
ISRCTN52370199已完成Unknown

Anti-migraine activity of supplement formulation (PEATONIDE®) based on the synergic combination of palmitoylethanolamide and melatonin

Erbozeta S.p.A.0 个研究点目标入组 60 人开始时间: 2024年8月6日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged 18 years old and over
  • 2. Diagnosis of episodic migraine (with or without aura) for at least one year before recruitment according to IHS-3 criteria
  • 3. At least two migraine attacks for at least three months before recruitment

排除标准

  • 1. Inconsistent supplement intake
  • 2. Regular uptake of analgesic drugs for more than 12 days per month
  • 3. Treatment with other supplements, or drugs, potentially having preventive effects on migraine

研究者

发起方
Erbozeta S.p.A.

相似试验